PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

Logo of capMary Ann Liebert, Inc.Mary Ann Liebert, Inc.JournalsSearchAlerts
Journal of Child and Adolescent Psychopharmacology
 

Table 1.

Demographic Characteristics, Clinical Characteristics, and Descriptive Statistics for All Study Measures for the Total Sample and by Clinical Predictor Subgroup

 
Total M (SD) or n (%)
Co-morbid DBD M (SD) or n (%)
 
Aggression M (SD) or n (%)
 
 n=65Yes (n=29)No (n=36)High (n=21)Low (n=39)
Age (years)10.85 (3.34)10.14 (3.30)11.52 (3.29)9.74 (3.56)11.11 (3.17)
Gender: male40 (61%)20 (69%)19 (53%)16 (76%)20 (51%)*
Ethnicity: White37 (57%)20 (69%)17 (48%)10 (48%)25 (64%)
Med.: Divalproex33 (50.8)17 (59%)16 (44%)10 (48%)21 (54%)
Med.: Risperidone32 (49.2)12 (41%)20 (56%)11 (52%)18 (46%)
Divalproex dose (mg/day)803.57 (300.00)796.05 (303.94)809.78 (303.55)812.50 (262.20)790.00 (330.17)
Riperidone dose (mg/day)1.35 (0.67)1.37 (0.69)1.34 (0.66)1.47 (0.72)1.25 (0.63)
Co-morbid DBD29 (45%)29 (100%)0 (0%)*10 (47.6%)16 (41%)
Co-morbid anxiety5 (8%)1 (3%)4 (11%)1 (5%)4 (11%)
Baseline OAS15.00 (8.53)16.42 (9.33)13.91 (7.84)24.86 (5.84)9.69 (3.53)*
Baseline YMRS28.72 (7.05)29.44 (7.24)28.12 (6.95)30.90 (7.39)27.59 (6.79)
Baseline CDRS=R41.38 (15.63)39.96 (12.78)42.50 (17.69)44.52 (17.69)39.85 (14.57)
Baseline CAFAS57.70 (49.21)67.41 (57.02)50.00 (41.27)100.48 (50.84)36.15 (29.79)*
Endpoint OAS2.98 (3.76)2.80 (4.10)3.14 (3.51)2.80 (4.23)2.96 (3.71)
Endpoint YMRS8.17 (8.70)8.30 (8.15)8.05 (9.39)8.73 (10.66)7.74 (7.94)
Endpoint CDRS=R26.40 (9.93)25.85 (10.57)26.91 (9.54)23.67 (9.83)27.63 (9.81)
Endpoint CAFAS17.01 (35.79)21.67 (36.31)12.35 (35.27)25.33 (43.73)11.00 (27.70)

Medication dosage refers to endpoint values.

*t-tests comparing groups=p<0.05.

DBD=disruptive behavior disorder; OAS=Overt Aggression Scale; YMRS=Young Mania Rating Scale; CDRS-R=Child Depression Rating Scale, Revised; CAFAS=Child and Adolescent Functional Assessment Scale; SD=standard deviation; Med.=medication type.